Acetic Acid 26, 254, 279, 289, 290, 316, 425, 446 Acetonitrile 47, 93

Total Page:16

File Type:pdf, Size:1020Kb

Acetic Acid 26, 254, 279, 289, 290, 316, 425, 446 Acetonitrile 47, 93 471 Index a – four-component reaction 462 acetic acid 26, 254, 279, 289, 290, 316, 425, 446 – primordial electrophilic activation of 346 acetonitrile 47, 93, 101, 114, 266, 267, 272, 280, aldehyde–indole condensation 352 389, 412 aldehydes 19, 26, 34, 42, 80, 87, 90, 92, 112, 130, acetylated carbohydroxylation product 403 133, 167, 225, 283, 293, 357, 415, 416, 1-acetylcyclopropanecarboxamides 119 429, 444, 458 acetylene carboxylates 351 – 1,3-dipolar cycloaddition of 454 acetylenedicarboxylates 351 – DMSO, oxidation in situ 384 acetylenes 333, 351, 368, 374 – four-component reaction 462 achiral and racemic multicomponent – lithium bis(trimethylsilyl)amide 326 reactions 111 – three-component cycloaddition of 455 – involving four reactive sites 139–142 – three-component reaction of 443 – involving one pronucleophilic reactive – trimethylsilylimines 326 site 111–115 aldol condensation 367, 368, 383 – involving three reactive sites 134–138 aldol reaction 115, 188, 195, 197 – involving two reactive sites 115–134 – three-component aldol-type reaction 463 acid chlorides 215, 343, 344, 354, 357 aldol-type product 416 – catalytic transformation of 342 alicyclic ketones 429 Acm-S-protected cysteines 244 aliphatic amines 90 acrolein 116, 149 aliphatic ketones 79 acrylate 184, 411, 419 alkaline Boc deprotection 339 acyclic alkanes 423 alkaloid-like polycyclic moieties 29 acyclic allenes 305 alkaloids 29, 121, 146, 162, 164, 176, 404, acyclic analogs 232 446, 455 acyclic anhydrides 395–398 alkaloid-type polycycles 162 acyclic/cyclic benzylamines 274 alkane carbonylation 421 acylamino-1,3-butadiene 26 alkenol partner, trapping of 417 acylhydrazine 422 alkenylidene oxazolidinones acyl iodide 421 – A3-carboxylative cyclization 337 1-acyloxy-1,3-butadiene derivatives 396 – four-component synthesis 337 N-acyloxyphthalimide 412 alkenynes carbocyclization 416 5-acylpyrid-2-ones alkoxyallenes 324, 326, 327 – coupling–amination–aza-annulation – three-component reaction 327 four-component synthesis 345 1-(alkoxyarylmethyl)indole-3-carboxyl – four-component synthesis of 345 esters 293 acyl radicals, nucleophilic reactivity 423 α-alkoxy-β-hydroxy esters 188 o-acyl-substituted cyclohexenes 26 2-alkoxyfuro[2,3-c]quinolines 286 α-adduct intermediate 275 alkoxyoxazoles 444 alcohols 346, 429, 433, 460–462 – three-component synthesis of 444 Multicomponent Reactions in Organic Synthesis, First Edition. Edited by Jieping Zhu, Qian Wang, and Mei-Xiang Wang. 2015 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2015 by Wiley-VCH Verlag GmbH & Co. KGaA. 472 Index alkoxy radical 426 – three-component synthesis of 364, 365 2-alkoxy-substituted 2,5-dihydropyrroles 326 – transition metal-catalyzed processes 333 6-alkoxy-tetrahydropyridines 122 alkynols 464 α-alkyl-α-diazoacetates 186 alkynones 342 N-alkyl amines, oxidation of 266 – catalytic generation of 341, 342 2-alkylamino-3-arylquinoxalines 288 2-(1-alkynyl)-2-alken-1-ones 208 – synthesis, postulated mechanism 288 2-alkynylanilines 293 2-[1-alkyl-5,6-bis(alkoxycarbonyl)-1,2,3, 3-alkynylated β-amino acid ethyl esters 4-tetrahydro-2-oxopyridin-3-yl]acetic acid – three-component synthesis 352 derivatives 390 γ,δ-alkynyl-β-amino acid esters α-alkyl diazoacetates 189 – Cu(II)-catalyzed three-component synthesis alkyl halides 117, 429 of 352 – abstract halogens 431 alkynyl benzaldehyde hydrazine – carbonylation 419 – Fischer carbene mediates a cyclization of 369 N-alkyl hydroxylamine 279 2-alkynylbenzaldehydes 283 alkylidenecyclopropanes 424 ortho-alkynyl benzaldehydes 349 alkylidene malonates 112 2-alkynyl benzaldehyde substrate 346 alkyl iodides 420 2-alkynylbiaryls 67, 68 – one-carbon homologation of 419 α-alkynyl enaminyl Pd species 339 2-(3-alkyl-4-oxo-2-thioxo-1,3-thiazinan-5-yl) α-alkynyl indoles 337 acetic acids – three-component synthesis of 338 – generation of 389 ortho-alkynyl phenyl isonitrile 348 – three-component synthesis 389 alkynyl sulfones 404 alkyl radical 422 allene reaction 322 alkyne 370, 422 allenes – 1,3-dipolar cycloaddition 357 – in heterocycles synthesis 301 – titanium-catalyzed four-component reaction – intramolecular Michael addition 303 of 370 – multicomponent reactions of 314 alkyne–imine MCRs 160 – palladium-catalyzed reactions 307, 308 alkynes 343 – reactions with acceptor-substituted – in cycloadditions 356 allenes 301 ––in Cu(I)-catalyzed 1,3-dipolar azide–alkyne –– catalyzed multicomponent reactions cycloaddition 358–366 316–318 –– dienophiles in MCRs 366–370 –– uncatalyzed multicomponent –– as dipolarophiles 356–358 reactions 318–323 – electrophiles, conversion 341–345 – reactions with donor-substituted – as electrophilic partners 351–356 allenes 301, 323–328 – as nucleophilic, electrophilic, dipolarophilic, – reactions with 1,2-propadiene 302 and dienophilic reaction partners 334 –– copper-, nickel-, and rhodium-promoted – as nucleophilic, exemplified reactivity multicomponent reactions 310–314 patterns of 334 –– multicomponent reactions without – π-nucleophilic reactivity 345–351 transition metals 314, 315 – σ-nucleophilic reactivity 335 –– palladium-catalyzed multicomponent –– alkyne–aldehyde–amine condensation– reactions 302–310 A3-coupling 335–337 α-allenic sulfonamides 306 –– alkyne–(hetero)aryl halide (sonogashira) allenic p-toluenesulfonamides coupling 337–341 – palladium-catalyzed carbonylation- –– electrophiles, acetylide additions 335 coupling-cyclization of 306 – organometallic MCRs, reaction rac-2,3-allenoates 455 partners 370–373 – 1,3-dipolar cycloaddition and kinetic – radical-mediated Cu-catalyzed three- resolution 456 component 366 allenoic acids 316 – terminal alkynyl C-H bonds 335 allenyl alcohols Index 473 – copper-mediated carbomagnesiation of 311 2-(1-aminoalkyl)-5-alkoxyoxazoles allenyl amidine 365 – Ugi-type three-component synthesis of 444 α-allenyl amines 2-(1-aminoalkyl)-5-aminoxazoles 443 – allenyl imine intermediates 310 α-amino amides 277, 412, 428 – palladium-catalyzed three-component – quaternary centers 429 cascade reaction 307 4-aminobenzo[b] [1,4]oxazepines allenyl imidothioate 324, 326 – three-component synthesis of 354, 355 allenyl imines 327 amino carbonyl compounds 273 1,2-allenyl ketones anti-β-amino carbonyls 440 – palladium-catalyzed carbonylative 2-amino-3,5-dicarbonitrile-6- dimerization of 316 thiopyridines 296 allenyl phosphonates 317 3-amino-3,4-dihydropyridinones 465 allenylsilane 315 amino esters – treatment 315 – 1,3-dipolar cycloaddition of 454 allyl acetoacetate 98 – three-component cycloaddition of 455 allyl chloride–aryne–alkyne coupling 60, 63 amino-functionalized ionic liquids 117 3-allyl N-cyanoindoles 348 2-amino-4-(5-hydroxy-3-methyl-1H-pyrazol- allylic alcohols 208 4-yl)-4H-chromene-3-carbonitrile allyl isocyanide 80 derivatives 138 π-allylpalladium species α-amino imides – cyclization of 310 – Ugi-type three-component reaction 277 – iodobenzene derivative, carbopalladation β-amino iso(thio)cyanates 17 of 303 α-aminomalonate 144 N-allylpyrimidines 103 5-aminooxazoles 244, 245 allyl-substituted hydroxypyrimidines 97 3-amino oxindoles 462 allyl sulfone 406 6-aminopenicillanic acid 4 allyl-tributylstannane 406 ortho-amino phenol 354 allyltrimethylsilane 395 – three-component synthesis of 354 Alternaria alternata 232 ortho-aminophenylacetylenes 368 alumina-promoted hydrolysis 287 4-amino-phthalazin-1(2H)-ones (APOs) 36 amide 277 – one-pot palladium-catalyzed MCR amidines toward 35, 36 – addition 423 5-aminopyrazole 21, 22 – formation 366 2-aminopyridines 292 – palladium-catalyzed synthesis 34 4-aminopyridines 84 amidinyl-substituted radicals 366 4-aminoquinolines 84 α-amido lactams α-amino-substituted alkoxyallenes 327 – oxidation–dehydration–Ugi reaction 273 4-amino-1,2,3,4-tetrahydroquinolines 447 amidomethyl-substituted 1,2,3-triazoles aminyl radicals 366 – three-component synthesis of 362, 363 ammonia 79, 94, 95, 109, 123, 126, 147, amido-substituted cyclohexadienes 367 386, 458 – substituted cyclohexadienes, pseudo-four- ammonium acetate 118 component synthesis of 367 – catalyzed, Hantzsch condensation reaction amines 26, 34, 36, 73, 90, 126, 222, 257, 305, of 459 389, 429, 430, 431, 432, 442 amphiphilic functionality, in situ – to 4CR products 387 generation 343 – four-component reaction 462 analgesic 393 – four-component reaction (4CR) 379 AnchorQueryTM 7 – Michael addition of 352 2- and 4-nitrophenols 78 syn-β-amino-αalkoxy esters 461 anellated azepines 357 aminoacetaldehyde dimethoxyacetal 96 anellated 4H-thiochromen-4-ones syn-β-amino-α-hydroxy esters 461 – three-component synthesis 343 1,2-amino alcohols 429 anellated isoquinolinium salts 346 474 Index angularly annulated furoquinolines – Diels–Alder adducts 390 – three-component synthesis of 369 β-aryloximes 403 anhydride-based multicomponent arylpalladium species 305 reactions 379 1-aryl-4-(2-phenylethynyl)[1,2,4]triazolo[4, anhydride used, in MCRs 3-a]quinoxalines – structures of 380 – four-component synthesis 339 anilines 188, 196, 464 N-aryl proline amides 30 – aldol-type reaction of 462 N-aryl-pyrrolidine-2-carboxamide 90, 91 – as amino substrates 335 N-arylpyrrolidine-2-thiocarboxamides 91 – aza-Diels-Alder reaction of 453 N-aryl thiocarboxamides 96 – Michael addition of 352 arynes 39 – three-component cycloaddition of 455 – based multicomponent reactions 41 – three-component reaction of 443 – 2,3-didehydrobenzofuran 39 annulated cyclohexadiene 372 – transition metal-catalyzed multicomponent annulated furoquinolines reactions 60 – ortho-aminophenylacetylenes 368 –– annulations 60, 61, 63–65 annulated hydroquinone 371, 372 –– cross-coupling-type reactions
Recommended publications
  • 7 X 11.5 Three Lines.P65
    Cambridge University Press 978-0-521-71413-6 - Antipsychotics and Mood Stabilizers: Stahl’s Essential Psychopharmacology, Third Edition Stephen M. Stahl Index More information Index Page numbers followed by ‘f ’ indicate figures; page numbers followed by ‘t ’ indicate tables. 3PPP, 134f agitation, benzodiazepines for, 188 AAADC (aromatic amino acid decarboxylase), and receptor conformation, 132f 97, 98f agranulocytosis, clozapine and, 164 ABT089, 203 akathisia acetylcholine (ACh), from aripiprazole, 175 in arousal pathways, 150, 152f nigrostriatal pathway dopamine deficiencies and blocked dopamine receptors, 93f and, 31 overactivity, 95 alanine-serine-cysteine transporter (ASC-T), reciprocal relationship with dopamine, 92f glial, 34 acetylcholine-linked mechanisms, 202 alogia, 5, 6t ACP 103, 200 alpha 1 adrenergic receptors ACP-104, 129, 134f atypical antipsychotic agents and, 139f ACR16, 134f and sedation, 151f adipose tissue, insulin resistance in, 141, alpha-1 receptor, antagonism, 94f 144f alpha-2 adrenergic receptors, atypical adolescence antipsychotic agents and, 139f aggressiveness in, 179 alpha 2 antagonists, 168 removal of synaptic connections, 68 alpha-4 beta-2 nicotinic acetylcholine receptor, risperidone for treating psychotic disorders, 203 166 alpha-7-nicotinic cholinergic agonists, affective blunting, 5 202 affective flattening, as SSRI side effect, 110 alpha amino-3-hydroxy-5-methyl-4- affective symptoms isoxazolepropionic acid (AMPA) dorsal vs. ventral regulation, 76f receptors, 40, 40f, 66f mesolimbic dopamine pathway role
    [Show full text]
  • Bimetallic Catalyst Catalyzed Carbonylation of Methanol to Acetic Acid
    materials Article Study on Rh(I)/Ru(III) Bimetallic Catalyst Catalyzed Carbonylation of Methanol to Acetic Acid Shasha Zhang 1, Wenxin Ji 1,2,*, Ning Feng 2, Liping Lan 1, Yuanyuan Li 1,2 and Yulong Ma 1,2 1 College of Chemistry and Chemical Engineering, Ningxia University, Yinchuan 750021, China; [email protected] (S.Z.); [email protected] (L.L.); [email protected] (Y.L.); [email protected] (Y.M.) 2 State Key Laboratory of High-efficiency Utilization of Coal and Green Chemical Engineering, Ningxia University, Yinchuan 750021, China; [email protected] * Correspondence: [email protected]; Tel.: +86-135-1957-9989; Fax: +86-951-206-2323 Received: 13 July 2020; Accepted: 3 September 2020; Published: 11 September 2020 Abstract: In this study, a Rh(I)/Ru(III) catalyst with a bimetallic space structure was designed and synthesized. The interaction between the metals of the bimetallic catalyst and the structure of the bridged dimer can effectively reduce the steric hindrance effect and help speed up the reaction rate while ensuring the stability of the catalyst. X-ray photoelectron spectroscopy (XPS) results show that rhodium accepts electrons from chlorine, thereby increasing the electron-rich nature of rhodium and improving the catalytic activity. This promotes the nucleophilic reaction of the catalyst with methyl iodide and reduces the reaction energy barrier. The methanol carbonylation performance of the Rh/Ru catalyst was evaluated, and the results show that the conversion rate of methyl acetate and the yield of acetic acid are 96.0% under certain conditions. Furthermore, during the catalysis, no precipitate is formed and the amount of water is greatly reduced.
    [Show full text]
  • 5-HT2A/2C Receptor Modulation of Absence Seizures and Characterization of the GHB-Model
    5-HT2A/2C receptor modulation of absence seizures and characterization of the GHB-model A thesis submitted to Cardiff University for the degree of Doctor of Philosophy by Marcello Venzi (MSc) School of Biosciences, Cardiff University, October 2014 Chapter 1 Declaration and Statements This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of PhD . Signed ………………………………………… (candidate) Date ………………………… STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. The views expressed are my own. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loans after expiry of a bar on access previously approved by the Academic Standards & Quality Committee. Signed ………………………………………… (candidate) Date ………………………… II Chapter 1 Summary Absence seizures (ASs) are non-convulsive epileptic events which are common in pediatric and juvenile epilepsies. They consist of EEG generalized spike-and-wave-discharges (SWDs) accompanied by an impairment of consciousness and are expressed within the thalamocortical network.
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • Step-By-Step Guide to Better Laboratory Management Practices
    Step-by-Step Guide to Better Laboratory Management Practices Prepared by The Washington State Department of Ecology Hazardous Waste and Toxics Reduction Program Publication No. 97- 431 Revised January 2003 Printed on recycled paper For additional copies of this document, contact: Department of Ecology Publications Distribution Center PO Box 47600 Olympia, WA 98504-7600 (360) 407-7472 or 1 (800) 633-7585 or contact your regional office: Department of Ecology’s Regional Offices (425) 649-7000 (509) 575-2490 (509) 329-3400 (360) 407-6300 The Department of Ecology is an equal opportunity agency and does not discriminate on the basis of race, creed, color, disability, age, religion, national origin, sex, marital status, disabled veteran’s status, Vietnam Era veteran’s status or sexual orientation. If you have special accommodation needs, or require this document in an alternate format, contact the Hazardous Waste and Toxics Reduction Program at (360)407-6700 (voice) or 711 or (800) 833-6388 (TTY). Table of Contents Introduction ....................................................................................................................................iii Section 1 Laboratory Hazardous Waste Management ...........................................................1 Designating Dangerous Waste................................................................................................1 Counting Wastes .......................................................................................................................8 Treatment by Generator...........................................................................................................12
    [Show full text]
  • 货号 英文名称 规格 D50673 A66 2.5Mg,5Mg,100Ul(10Mm/DMSO
    货号 英文名称 规格 D50673 A66 2.5mg,5mg,100ul(10mM/DMSO) D50690 Acadesine 25mg,50mg,1ml(10mM/DMSO) D50691 Acadesine phosphate 10mg,25mg,1ml(10mM/DMSO) D50580 Acemetacin 500mg D50669 Acetohexamide 25mg,50mg,1ml(10mM/DMSO) D50574 Acrivastine 10mg D50409 Actinomycin D 1mg D50409s Actinomycin D (10mM in DMSO) 100ul D50553 Adavosertib 5mg D50619 Adenosine 5'-monophosphate monohydrate 100mg,250mg,1ml(10mM/DMSO) D50412 Adriamycin 10mg,50mg D50412s Adriamycin (10mM in DMSO) 200ul D50381 AEBSF 10mg,100mg D50381s AEBSF solution (10mM) 100ul D50600 Afloqualone 10mg,50mg,1ml(10mM/DMSO) D50575 Alcaftadine 5mg D50556 Alosetron 2.5mg D50557 Alosetron Hydrochloride 100mg D50675 Alpelisib 5mg,10mg,200ul(10mM/DMSO) D50616 Alvelestat 1mg,2mg,200ul(10mM/DMSO) D50577 Alvimopan dihydrate 1mg,5mg D50581 Amfenac Sodium Hydrate 100mg D50653 AMG 208 2.5mg,200ul(10mM/DMSO) D50645 AMG319 2mg,5mg,100ul(10mM/DMSO) D50547 Amonafide 5mg D50614 Anacetrapib 5mg,10mg,200ul(10mM/DMSO) D50670 Anethole trithione 100mg,500mg,1ml(10mM/DMSO) D50667 Anhydroicaritin 5mg,10mg,1ml(10mM/DMSO) D52001 Anisomycin 5mg,10mg D50578 Antineoplaston A10 1mg,5mg D50530 Antipain dihydrochloride 1mg,5mg D50671 Antipyrine 10mg,50mg,1ml(10mM/DMSO) D50627 Apararenone 5mg,200ul(10mM/DMSO) D50624 Apixaban 10mg,50mg,1ml(10mM/DMSO) D10360 Aprotinin (5400 KIU/mg) 10mg,25mg,100mg D50507 Arbidol hydrochloride 10mg D50508 Arbidol Hydrochloride Hydrate 500mg D50620 ATP 5g,10g,1ml(10mM/DMSO) D50621 ATP disodium salt hydrate 1g,10g,1ml(10mM/H2O) D50635 Baicalein 100mg,1ml(10mM in DMSO) D50400 b-AP15 5mg D50400s b-AP15
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed Et Al
    US0078.93053B2 (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed et al. (45) Date of Patent: Feb. 22, 2011 (54) TREATING PSYCHOLOGICAL CONDITIONS WO WO 2006/127418 11, 2006 USING MUSCARINIC RECEPTORM ANTAGONSTS (75) Inventors: Brian Seed, Boston, MA (US); Jordan OTHER PUBLICATIONS Mechanic, Sunnyvale, CA (US) Chau et al. (Nucleus accumbens muscarinic receptors in the control of behavioral depression : Antidepressant-like effects of local M1 (73) Assignee: Theracos, Inc., Sunnyvale, CA (US) antagonist in the porSolt Swim test Neuroscience vol. 104, No. 3, pp. 791-798, 2001).* (*) Notice: Subject to any disclaimer, the term of this Lind et al. (Muscarinic acetylcholine receptor antagonists inhibit patent is extended or adjusted under 35 chick Scleral chondrocytes Investigative Ophthalmology & Visual U.S.C. 154(b) by 726 days. Science, vol.39, 2217-2231.* Chau D., et al., “Nucleus Accumbens Muscarinic Receptors in the (21) Appl. No.: 11/763,145 Control of Behavioral Depression: Antidepressant-like Effects of Local M1 Antagonists in the Porsolt Swin Test.” Neuroscience, vol. (22) Filed: Jun. 14, 2007 104, No. 3, Jun. 14, 2001, pp. 791-798. Bechtel, W.D., et al., “Biochemical pharmacology of pirenzepine. (65) Prior Publication Data Similarities with tricyclic antidepressants in antimuscarinic effects only.” Arzneimittelforschung, vol. 36(5), pp. 793-796 (May 1986). US 2007/O293480 A1 Dec. 20, 2007 Chau, D.T. et al., “Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local Related U.S. Application Data Mantagonist in the Porsolt Swim test.” Neuroscience, vol. 104(3), (60) Provisional application No.
    [Show full text]
  • Davey KJ Phd 2013.Pdf
    UCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks! Title The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction Author(s) Davey, Kieran Publication date 2013 Original citation Davey, K. 2013. The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction. PhD Thesis, University College Cork. Type of publication Doctoral thesis Rights © 2013. Kieran Davey http://creativecommons.org/licenses/by-nc-nd/3.0/ Embargo information Restricted to everyone for one year Item downloaded http://hdl.handle.net/10468/1243 from Downloaded on 2021-10-09T20:00:22Z Ollscoil na hEireann National Unversity Ireland Colaiste na hOllscoile, Corcaigh University College Cork School of Pharmacy The Gut Microbiota as a Contributing Factor to Antipsychotic-Induced Weight Gain and Metabolic Dysfunction Thesis presented by Kieran J. Davey under the supervision of Prof. John F. Cryan Prof. Timothy G. Dinan Dr Siobhain M. O’Mahony for the degree of Doctor of Philosophy Head of School: CatrionaO’Driscoll Contents Declaration ........................................................................................................................................... vii Acknowledgements .......................................................................................................................... viii Publications and presentations .....................................................................................................
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • Chapter -1 Introduction, Review of Literature And
    CHAPTER -1 INTRODUCTION, REVIEW OF LITERATURE AND SCOPE OF THE PRESENT WORK 1 INTRODUCTION The heterocycles play an important part in the metabolism of all living cells and find important applications in industry.1 Among these important substances, such vitamins and coenzymes precursors as thiamine, riboflavin, nicotinic acid, adenine, biotin, vitamin Bi2, vitamin E, photosynthesizing pigment chlorophyll, the oxygen-transporting pigment haemoglobin, the purine and pyrimidine which are the components of the nucleic acids, and their metabolic products such as uric acid, allantoin, and alloxan to the amino-acids like histidine, tryptophan, proline, and the harmones such as kinetin, zeatin, heteroauxin and histamine contain heterocyclic ring system in them. Many of the drugs, natural as well as synthetic, which are in regular use are heterocyclic compounds. The several natural drugs such as alkaloids, the cardiac glycosides and antibiotics such as penicillin contain heterocyclic ring in them. Some other synthetic heterocyclic compounds are numerous and include barbiturates, thiouracil, carbimazole, 9-aminoacridine, 8-hydroxyquinoline, and vasoprassor modifiers. Polyvinylpyrrolidone are used as a replacement for serum lost in haemorrhage and shock. Many pesticides and weed killers such as paraquat, diquat and simazine; insecticides such as rotenone, diazinon, menazon; anthelminitics such as phenothiazine, thiabendazoles; rodenticides such as warfarin are heterocyclic compounds. The heterocycles are acting as the antidotes for poisoning due to the phosphorus insecticides, such as pyridine-2-aldoxime methiodide. The current use of the heterocycles in drugs and pesticides is due to the high resistance of heterocyclic substances to biological degradation. In addition to the drug value the synthetic heterocyclic compounds acts as chemotherapeutic agents, dyestuffs and co-polymers.
    [Show full text]
  • Induced Obesity Xu-Feng Huang University of Wollongong, Xuzhou Medical University, [email protected]
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Research Online University of Wollongong Research Online Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health 2018 Decreased 5‐HT2cR and GHSR1a interaction in antipsychotic drug‐induced obesity Xu-Feng Huang University of Wollongong, Xuzhou Medical University, [email protected] Katrina Weston-Green University of Wollongong, [email protected] Y Yu Xuzhou Medical University, University of Wollongong Publication Details Huang, X., Weston-Green, K. & Yu, Y. (2018). Decreased 5‐HT2cR and GHSR1a interaction in antipsychotic drug‐induced obesity. Obesity Reviews, 19 (3), 396-405. Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [email protected] Decreased 5‐HT2cR and GHSR1a interaction in antipsychotic drug‐induced obesity Abstract Second generation antipsychotics (SGAs), notably atypical antipsychotics includingolanzapine, clozapine and risperidone, can cause weight gain and obesity side ef-fects. Antagonism of serotonin 2c receptors (5-HT2cR) and activation of ghrelin re-ceptor type 1a (GHSR1a) signalling have been identified as a main cause of SGAinduced obesity. Here we review the pivotal regulatory role of the 5-HT2cR inghrelin-mediated appetite signalling. The 5-HT2cR dimerizes with GHSR1a to in-hibit orexigenic signalling, while 5-HT2cR antagonism reduces dimerization andincreases GHSR1a-induced food intake. Dimerization is specific ot the unedited5-HT2cR isoform. 5-HT2cR antagonism by SGAs may disrupt the normal inhibi-tory tone on the GHSR1a, increasing orexigenic signalling. The 5-HT2cR and itsinteraction with the GHSR1a could serve as the basis for discovering novel ap-proaches to preventing and treating SGA-induced obesity.
    [Show full text]
  • Surface Characterization and Reactivity of Methylammionium Lead Iodide
    Surface Characterization and Reactivity of Methylammionium Lead Iodide by Kenneth Zielinski A Thesis Submitted to the Faculty of the WORCESTER POLYTECHNIC INSTITUTE in partial fulfillment of the requirements for the Master of Science Degree in Chemistry October 2018 APPROVED: Assistant Professor Ronald L. Grimm, Advisor Associate Professor N. Aaron Deskins, Committee Member Associate Teaching Professor Christopher Lambert, Committee Member Associate Professor Shawn Burdette, Committee Member Professor Arne Gericke, Department Head 1 Abstract We quantify the chemical species present at and reactivity of the tetragonal (100) face of single-crystal methylammonium lead iodide, MAPbI3(100). MAPbI3 is an ABX3 perovskite, experiments utilized the orthogonal reactivity of the A+-site cation, the B2+-site – cation, and the X -site halide anion. Ambient-pressure exposure to BF3 solutions probe the reactivity of interfacial halides. Reactions with p-trifluoromethylanilinium chloride probe the exchange reactivity of the A+-site cation. The ligand 4,4’-bis(trifluoromethyl)- 2,2’-bipyridine probe for interfacial B2+-site cations. Fluorine features in x-ray photoelectron spectroscopy (XPS) quantify reaction extents with each solution-phase species. XP spectra reveals adsorption of BF3 indicating surface-available halide anions on tetragonal MAPbI3(100) and preliminary examinations on the (112), (110), and thin- film surfaces. Temperature-programmed desorption (TPD) established a ~200 kJ mol–1 desorption activation energy from tetragonal MAPbI3(100). Adsorption of the fluorinated anilinium cation includes no concomitant adsorption of chlorine as revealed by the absence of Cl 2p features within the limits of XPS detection on the tetragonal (100) and (112) faces with no discernable exchange in preliminary experiments on tetragonal (110).
    [Show full text]